Question follow-through · 43867

Voluntary Scheme for Branded Medicines Pricing, Access and Growth

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the repayment rate for newer medicines under the Voluntary Scheme for Branded Medicines Pricing, Access and Growth on the UK life sciences sec

answeredDepartment of Health and Social Care

About this written question

A written question asks a government minister for information in writing. Parliament publishes the question and any answer.

Answering body: Department of Health and Social Care
Tabled: 3 Apr 2025
Target answer date: 7 Apr 2025
Answer: 9 Apr 2025 · 6 calendar days after tabling

Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.

Votes on this topic

These Commons divisions share a topic label. The question did not necessarily lead to a vote.

Recorded timeline

3 Apr 2025
Question tabled
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the repayment rate for newer medicines under the Voluntary Scheme for Branded Medicines Pricing, Access and Growth on the UK life sciences sec
7 Apr 2025
Target answer date
Date supplied by the official written-questions record.
9 Apr 2025
Answer published
The voluntary scheme for branded medicines pricing, access, and growth (VPAG) is a unique partnership between the Government and the pharmaceutical industry and includes a range of commitments to support innovation and improve National Health Service acce...

Open official record

Official data retrieved 28 Sept 2026.

Later records

Possible follow-up questions

Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Clinical Trials

4 Jun 2025 · To ask the Secretary of State for Health and Social Care, what assessment he has made of the capacity of local health committees to respond promptly to local clinical trial requests.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

DNA: Testing

18 Jun 2025 · To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the (a) data protection and (b) ethical implications of commercial DNA testing services used by minors without age verification.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

DNA: Screening

24 Jun 2025 · To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of introducing regulatory standards for the marketing of consumer DNA testing kits.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Obesity: North East

11 Jul 2025 · To ask the Secretary of State for Health and Social Care, whether he has had recent discussions with relevant stakeholders on strategies for reducing child obesity in the North East.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Palliative Care: Access

11 Jul 2025 · To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that the 10-Year Plan for Health delivers equitable access to (a) palliative and (b) end of life care across all communities.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Palliative Care: Access

11 Jul 2025 · To ask the Secretary of State for Health and Social Care, if his Department will publish further details on plans to expand the provision of (a) palliative and (b) end of life care in community settings as outlined in the 10-Year Plan for Health.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Knee Replacements

14 Jul 2025 · To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential (a) financial and (b) clinical impact of the Zimmer Biomet NexGen Legacy Posterior Stabilized (LPS) knee replacement system on the NHS.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Arthritis: Health Services

16 Jul 2025 · To ask the Secretary of State for Health and Social Care, what steps he is taking to improve care for people with arthritis.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Chronic Illnesses: Health Services

16 Jul 2025 · To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the 10 Year Health Plan supports people with (a) arthritis and (b) other long-term conditions.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Health: Disadvantaged

16 Jul 2025 · To ask the Secretary of State for Health and Social Care, what steps his Department is taking to tackle health inequalities in the North East.

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Musculoskeletal Disorders: Research

20 Oct 2025 · To ask the Secretary of State for Health and Social Care, with reference to Action 10 on page 22 of the Life Sciences Sector Plan, published on 16 July 2025, what steps his Department is taking to ensure that musculoskeletal conditions are included in pla

Unreviewed candidateSame MP and department; topic relationship is unreviewed

Health Services: Innovation

21 Oct 2025 · To ask the Secretary of State for Health and Social Care, who is responsible for the (a) national and (b) regional (i) adoption and (ii) spread of health innovation within the NHS; and what role the Health Innovation Network and Integrated Care Systems pl